News & Updates

Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.

Urgency urinary incontinence is common among women with bacterial vaginosis, according to a study.

Diagnosis, progression, or death due to prostate cancer occur at approximately a decade to 15 years following an initial assessment of prostate-specific antigen (PSA) levels in older men, according to a study presented at EAU 2022.

In men with intermediate- or high-risk prostate cancer (PCa), local failure after definitive radiation therapy (RT) is indicative of survival outcomes, according to a recent study.